Abstract
The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative, led by the US Food and Drug Administration (FDA), aims to improve preclinical cardiac safety evaluation and reduce unwarranted drug attrition by utilizing more comprehensive model systems. A major component of CiPA is the development of an electrophysiological assay using human stem cell-derived cardiomyocytes (hSC-CMs), which provide an integrated assessment of the multiple ion channels contributing to the cardiac action potential (AP). This chapter details the current CiPA protocol for evaluating drug-induced changes in hSC-CM electrophysiology using microelectrode array (MEA) technology. In this assay, electrodes embedded in a cell culture substrate noninvasively interface with established cardiomyocyte networks, providing functional, mechanistically based measures of the cardiac action potential without perturbing the cellular network. Introduction of multiwell MEA technology has significantly increased assay throughput, enabling development efforts that further demonstrate the predictivity and reliability of MEA assays for evaluation of cardiac safety liability. Following a review of MEA theory and the field potential (FP) signal, this chapter provides a step-by-step protocol for MEA plate preparation and maintenance, assay execution, and data analysis according to the current CiPA guidelines. Alternative approaches to the MEA assay are also discussed, along with commentary on emerging advances in MEA technology for the assessment of cardiac safety liability in vitro.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Thomas CA, Springer PA, Loeb GE, Berwald-Netter Y, Okun LM (1972) A miniature microelectrode array to monitor the bioelectric activity of cultured cells. Exp Cell Res 74(1):61–66
Reppel M, Igelmund P, Egert U, Juchelka F, Hescheler J, Drobinskaya I (2007) Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 19(5–6):213–224
Meiry G, Reisner Y, Feld Y, Goldberg S, Rosen M, Ziv N, Binah O (2001) Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes. J Cardiovasc Electrophysiol 12(11):1269–1277
Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, January CT (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301:2006–2017
Clements M, Thomas N (2014) High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol Sci 140(2):445–461
Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134(2):412–426
Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Wu JC (2013) Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128(11 Suppl 1):S3–S13
Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL (2010) Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4(2):107–116
Gilchrist KH, Lewis GF, Gay EA, Sellgren KL, Grego S (2015) High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol Appl Pharmacol 288(2):249–257
Spach MS, Barr RC, Serwer GA, Kootsey JM, Johnson EA (1972) Extracellular potentials related to intracellular action potentials in the dog Purkinje system. Circ Res 30(5):505–519
Breckenridge LJ, Wilson RJ, Connolly P, Curtis AS, Dow JA, Blackshaw SE, Wilkinson CD (1995) Advantages of using microfabricated extracellular electrodes for in vitro neuronal recording. J Neurosci Res 42(2):266–276
Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Sawada K (2015) Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 75:17–26
Bove M, Grattarola M, Martinoia S, Verreschi G (1995) Interfacing cultured neurons to planar substrate microelectrodes: characterization of the neuron-to-microelectrode junction. Bioelectrochem Bioenerg 38(2):255–265
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32–45
Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167(3):292–300
Gintant, G. et al. (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat. Rev. Drug Discov., 15, 457–71
Nakamura, Y. et al. (2014) Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study. J. Pharmacol. Sci., 124, 494–501
Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Miyamoto N (2015) CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia—effects of 7 reference compounds at 10 facilities. J Pharmacol Toxicol Methods 78:93–102
Clements M (2016) Multielectrode array (MEA) assay for profiling electrophysiological drug effects in human stem cell-derived cardiomyocytes. Curr Protoc Toxicol 68:22.4.1–22.4.32
Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 8(9):1263–1268
Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K (2011) Optogenetics in neural systems. Neuron 71(1):9–34
Clements, I.P., Millard, D.C., Nicolini, A.M., Preyer, A.J., Grier, R., Heckerling, A., Blum, R.A., Tyler, P., McSweeney, K.M., Lu, Y.F. and Hall, D., 2016, March. Optogenetic stimulation of multiwell MEA plates for neural and cardiac applications. In SPIE BiOS (pp. 96902C-96902C). International Society for Optics and Photonics
Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, Stoelzle-Feix S, Becker N, Fertig N, January CT, Anson BD, Ross JD. (2016) Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes. Toxicol. Sci., kfw153
Clements M, Millar V, Williams AS, Kalinka S (2015) Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment. Toxicol Sci 148(1):241–260
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Millard, D.C., Clements, M., Ross, J.D. (2017). The CiPA Microelectrode Array Assay with hSC-Derived Cardiomyocytes: Current Protocol, Future Potential. In: Clements, M., Roquemore, L. (eds) Stem Cell-Derived Models in Toxicology. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6661-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6661-5_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6659-2
Online ISBN: 978-1-4939-6661-5
eBook Packages: Springer Protocols